June 10, 2021: Trauma, burden, and COVID-19 risk among PLWH; sleep and viral suppression; spirituality/religioisity, depression, and HIV risk; why anal cancer screening isn't enough.
June 17, 2021: PrEP awareness vs. PrEP willingness among young Black women; acute HIV infection during PrEP initiation; real-world PrEP efficacy; HIV rates by U.S. region among transgender people.
June 3, 2021: Kaposi sarcoma despite ART; heat-based cervical HPV treatment; re-evaluating HIV-associated neurocognitive disorder; HIV and diabetes in Texas.
May 27, 2021: Recycling tenofovir in a second-line regimen; real-life two-drug regimen failure rates; jump-starting ART at sexual health clinics; viability of wearable devices in sleep assessment.
May 20, 2021: HIV testing and prevalence trends in the U.S.; groups at higher risk for losing viral suppression; intent vs. reality in making clinic appointments; transitioning from pediatric to adult HIV care.
May 13, 2021: Disparities in U=U awareness; sexual satisfaction trends among PLWH; PrEP use among cis women; HCV epidemiology in trans women.
May 6, 2021: Epigenetic aging and HIV treatment initiation; effects of ART on cognitive decline; dearth of osteoporosis screenings for PLWH; physical therapy vs. opioids for bone/muscle pain.
April 29, 2021: Measuring HIV drug susceptibility amidst extensive resistance; the reversibility of virologic failure; mobile HIV care in urban settings; whether to prescribe long-acting antiretroviral therapy.
April 22, 2021: Weight gain and CVD risk after treatment initiation; stroke type divergence among PLWH; exercise and CD4; a new approach to pain research in HIV.
April 15, 2021: Alcohol and neurocognitive impairment; using hair analysis to measure substance use; integrase inhibitors' impact on verbal learning; hepatocellular carcinoma trends among PLWH.
April 8, 2021: PrEP “contemplation” and uptake among adolescents; adolescent perception of HIV risk; HIV diagnosis rates among transgender people; PrEP and HIV incidence in Scotland.